Iretig

Mirabegron, the active ingredient in Iretig, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency, and incontinence in adult patients.

GNH USA supplies Iretig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution with comprehensive regulatory support.

Mirabegron is used to manage symptoms of overactive bladder, a condition characterized by urinary urgency, frequency, and incontinence.

Overactive bladder: increases bladder capacity and reduces urgency episodes. Urinary urgency: lessens the intensity and frequency of sudden urges to void. Urinary frequency: decreases the number of daytime voids.

Adverse reactions reported with Mirabegron include both common and less frequent events.

Common Side Effects: - Hypertension - Headache - Nasopharyngitis - Constipation - Dry mouth - Dizziness

Serious or Rare Side Effects: - Severe hypertension - Urinary retention leading to bladder obstruction - Allergic reactions such as rash, angioedema, or anaphylaxis - Tachycardia - Myocardial infarction (rare)

When prescribing Mirabegron, clinicians should consider several safety precautions.

Assess blood pressure before initiating therapy: ensure baseline values are within acceptable range. Monitor for urinary retention: watch for signs of incomplete bladder emptying. Review concomitant anticholinergic use: combined effects may increase retention risk. Adjust dose in renal impairment: dose modification may be required based on renal function. Avoid use in uncontrolled hypertension: contraindicated in patients with high baseline pressures. Store at room temperature: keep in the original pack, protect from moisture and light.

Mirabegron may interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) - Combined use with anticholinergic agents may increase urinary retention risk

Moderate Interactions (Monitor Closely): - Diuretics (may affect blood pressure control) - NSAIDs (potential additive hypertension) - Antihypertensive agents (possible reduction in antihypertensive effect) - Other β3‑adrenergic agonists (additive pharmacodynamic effect)